Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Pacific Biopharma: Two Parts US; One Part China

publication date: Jun 27, 2008

A San Diego contract manufacturer that specializes in biologics production, a California academic-business consortium, and the government of Taizhou, China are getting together to build a 200,000 square foot CMO facility in China that will focus on cost-effective small-batch manufacturing of biologic products. The new venture will be called Pacific Biopharma. San Diego’s PacificGMP, a three-year-old contract manufacturing enterprise, will contribute its experience with small-batch biologics manufacturing. QB3, a consortium of three University of California Universities and business leaders, will throw in its contacts and desire to produce prospective biologic drugs in small quantities. And the Taizhou government will invest an unspecified amount of money to build the new facility. More details... 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital